Built-for-purpose Biomarker Solutions Enhancing Speed, Precision, and Confidence

Syngene, with its comprehensive biomarker services spanning discovery, validation, and context‑of‑use assays, enables early decision‑making, patient stratification, and precision‑led drug development.

Author

Latest Blogs

Future-Ready QC Labs in Pharma 4.0: How Automation, Biometrics, and VR Are Redefining Quality Standards in India

Syngene booth at CPHI Japan 2026 with visitors and team members in discussion

CPHI Japan 2026 Takeaways: Why supply chain diversification is redefining CDMO trust in Japan

Decoding the FDA’s AMT program through process analytical technology

Infographic showing gene editing applications across the drug development pipeline.

Gene editing in 2025: from CRISPR to next generation platforms

AI drug discovery workflow for small molecule design

AI Drug Discovery: The Future of Small Molecule Design

Tirbanibulin and targeted dermal delivery in topical drug development